History of the development of arsenic derivatives in cancer therapy

Oncologist

Volumn 6, Issue SUPPL. 2, 2001, Pages 3-10

  Waxman, Samuel ^a   Anderson, Kenneth C ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Acute promyelocytic leukemia; Apoptosis; Arsenic trioxide

Indexed keywords

ARSENIC DERIVATIVE; ARSENIC TRIOXIDE;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CYTOLOGY; DRUG EFFICACY; DRUG SAFETY; HISTORY OF MEDICINE; PRIORITY JOURNAL; TRYPANOSOMIASIS;

EID: 0035038845     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_2-3     Document Type: Conference Paper

References (48)

1. Arsenic and old myths
2. More than a coincidence? The arrival of arsenic and the disappearance of plague in early modern Europe
3. Heavy metals and heavy-metal antagonists
4. Therapeutic mule: The use of arsenic in the nineteenth century materia medica
5. Delicious poison: Arsenic trioxide for the treatment of leukemia
6. Arsenic as a therapeutic agent in chronic myelogenous leukemia
7. Action of iron, cod-liver oil, and arsenic on the globular richness of the blood
8. Chronic arsenical poisoning during the treatment of chronic myeloid leukemia
9. Chemotherapy studies in an animal tumor spectrum. II. Sensitivity of tumors to fourteen antitumor chemicals
10. The use of selected sulfhydryl inhibitors in a preferential drug attack on cancer
11. Arsenic and cancer
12. Medicinal arsenic and internal malignancies
13. Arsenic carcinogenesis in animals and in humans: Mechanistic, experimental, and epidemiological evidence
14. Re: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
15. Arsenic: Evidence of carcinogenicity in animals
16. Long-term survivors of childhood cancer: The late effects of therapy
17. Treatment of adult acute leukemia
18. Second cancers following pediatric Hodgkin's disease
19. Abnormalities of the thyroid in survivors of Hodgkin's disease: Data from the Childhood Cancer Survivor Study
20. Arsenic - New life for an old potion
21. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
22. Al-Lin 1 treated 32 cases of acute promyelocytic leukemia
23. 3) in the treatment of APL: II. Remission induction in relapsed patients and pharmacokinetics
24. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
25. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
26. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3)
27. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines
28. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner
29. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins
30. Arsenic trioxide, a novel mitochondriotoxic anticancer agent?
31. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells
32. Mitochondrial intermembrane junctional complexes and their role in cell death
33. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
34. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through rrtodulation of the glutathione redox system
35. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells
36. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo
37. Caspases: The executioners of apoptosis
38. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases
39. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
40. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
41. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells
42. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
43. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis
44. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown
45. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
46. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
47. 1 phase accumulation by arsenic trioxide in an adult T-cell leukemia cell line, MT-1
48. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro